Establishing new use criteria led to an 86% reduction in the utilization of sugammadex with no appreciable impact on measured outcomes.
Andrea Reed, PharmD, MBA, BCPS, DPLA
Advertisement
Articles by Andrea Reed, PharmD, MBA, BCPS, DPLA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
4
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
5
